JPMorgan Chase & Co. Reduces Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

JPMorgan Chase & Co. reduced its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 10.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,057,167 shares of the company's stock after selling 119,024 shares during the period. JPMorgan Chase & Co. owned about 0.27% of Recursion Pharmaceuticals worth $7,146,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after purchasing an additional 9,737,196 shares in the last quarter. Geode Capital Management LLC grew its holdings in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock worth $35,803,000 after acquiring an additional 656,003 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Recursion Pharmaceuticals by 17.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock valued at $15,372,000 after acquiring an additional 333,323 shares in the last quarter. Vestmark Advisory Solutions Inc. raised its stake in shares of Recursion Pharmaceuticals by 15.3% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 845,154 shares of the company's stock worth $5,713,000 after acquiring an additional 112,221 shares during the last quarter. Finally, Platinum Investment Management Ltd. grew its stake in shares of Recursion Pharmaceuticals by 293.9% during the fourth quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company's stock valued at $4,955,000 after purchasing an additional 546,929 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on RXRX shares. Morgan Stanley cut their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Trading Up 3.4 %

Shares of NASDAQ RXRX traded up $0.18 during midday trading on Friday, reaching $5.50. The stock had a trading volume of 12,710,040 shares, compared to its average volume of 12,004,554. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company's 50 day moving average price is $6.66 and its 200 day moving average price is $6.80. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -3.59 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company's revenue for the quarter was down 57.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.42) EPS. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.